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Abstract
Background: Publication of results from the Women's Health Initiative study in July 2002 was a
landmark event in biomedical science related to postmenopausal women. The purpose of this study
was to describe the impact of new hormone therapy recommendations on patients' attitudes and
decision-making in a primary care practice.
Methods: A questionnaire including structured and open-ended questions was administered in a
family practice office waiting room from August through October 2003. Rationale for taking or not
taking hormone therapy was specifically sought. Women 50–70 years old attending for office visits
were invited to participate. Data were analyzed qualitatively and with descriptive statistics. Chart
review provided medication use rates for the entire practice cohort of which the sample was a
subset.
Results: Respondents (n = 127) were predominantly white and well educated, and were taking
hormone therapy at a higher rate (38%) than the overall rate (26%) for women of the same age
range in this practice. Belief patterns about hormone therapy were, in order of frequency, 'use is
risky', 'vindication or prior beliefs', 'benefit to me outweighs risk', and 'unaware of new
recommendations'. Twenty-eight out of 78 women continued hormones use after July 2002. Of 50
women who initially stopped hormone therapy after July 2002, 12 resumed use. Women who had
stopped hormone therapy were a highly symptomatic group. Responses with emotional overtones
such as worry, confusion, anger, and grief were common.
Conclusion: Strategies for decision support about hormone therapy should explicitly take into
account women's preferences about symptom relief and the trade-offs among relevant risks. Some
women may need emotional support during transitions in hormone therapy use.
Background
A highly publicized reversal in recommendations for
menopausal hormone therapy (HT) occurred in July 2002
when results were reported from the estrogen plus pro-
gestogen therapy (EPT) vs. placebo arm of the Women's
Health Initiative (WHI)[1]. HT is no longer recom-
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mended for disease prevention, while use for treatment of
menopausal symptoms for limited duration is still accept-
able. This was an abrupt reversal in recommendations that
represents a unique opportunity to study patient reactions
to the change.
A telephone survey conducted among staff model health
maintenance organization members in early 2003 [2]
identified that women had poor knowledge of the WHI
results despite directed mailings about the study findings
in July through August 2002, and that a little over half of
users' had attempted to stop HT after WHI results were
released[3]. One quarter of such women resumed HT
use[4,5].
The purpose of this study was to explore how women
seeking care in a primary care setting have experienced the
impact of the new recommendations on their attitudes
and decisions about HT from a qualitative perspective.
Methods
Subjects and setting
Since current recommendations discourage use of HT
except for symptomatic relief of menopausal symptoms,
care-seeking women were the population of interest rather
than a community-based sample. The study was con-
ducted in the waiting room of a faculty family medicine
clinic serving a predominantly white non-Hispanic popu-
lation (about 65%) in a small urban/suburban university
community. Women aged 50–70 attending for office vis-
its were invited to participate. A priori judgment was that
100 respondents would ensure a broad sampling of the
qualitative data. Enrollment was assessed at the end of
each month of data collection until that sample size was
reached.
Instrument
A questionnaire including open-ended questions regard-
ing women's HT decisions was developed for this study
(See Additional file 1). Questions included current views
about HT and change in views after July 2002. Reading
level was approximately eighth grade. Pilot testing con-
sisted of obtaining feedback on understandability and
acceptability from three women in the appropriate age
group with high school education.
Data collection and analysis
Self-administered questionnaires were located at the
reception desk next to the sign-in sheet for office visits. A
sign posted above the surveys invited women in the
appropriate age range to complete one and return it to the
receptionist. A brief explanation of the purpose of the
questionnaire was, " to know more about the use of hor-
mone replacement therapy by women in this clinic, and
how and why it may be changing". The survey was anon-
ymous and was granted exempt status by the University
Committee on Research in Human Subjects of Michigan
State University.
Data were analyzed at the conclusion of the data collec-
tion period. Numeric codes for descriptive data were
assigned and entered into an Access database. Transcribed
responses to each free-text question were first analyzed by
LMF who generated a list of labels and numeric codes to
summarize each concept. A second researcher reviewed
the coding scheme for each question for accuracy and
completeness. Two independent researchers coded each
question using multiple codes when indicated. Disagree-
ments were resolved by discussion. Major themes in the
responses were identified by consensus.
A chart review of the electronic medical record for this
practice was performed as a measure of comparison
between the study sample and the entire clinic population
of which the sample is a subset. HT prescribing rates were
determined for the whole clinic population of women in
the same age range during the study window and during
the previous 2 years, based on the presence or not of an
estrogen-containing product in the list of active medica-
tions.
Results
Sample characteristics
There were 133 surveys collected from August through
October 2003. Six questionnaires were excluded because
year of birth was either missing or outside of the target age
range, leaving 127 for analysis. This represents 15% of
847 active female patients born 1933–1952 seen in this
practice, and 30% of 419 women of appropriate age with
an office visit during the study timeframe.
Demographic characteristics of respondents and health-
related quantitative variables are displayed in Table 1.
Respondents were mostly non-Hispanic Caucasians and
well educated. Thirty-sex percent of survey respondents
were currently taking HT. Ninety-four women (74%) had
used HT for more than 5 years including 54 (43%) for
more than 10 years. The rate of HT use in the entire prac-
tice decreased from 49% during the year prior to July 2002
to 26% at the time of the survey.
Belief patterns
Four general patterns of belief were identified from the
data analysis, labeled 'use is risky' (n = 86), 'vindication of
prior beliefs' (n = 14), 'benefit to me outweighs risk' (n =
10), and 'unaware of new recommendations' (n = 9).
Seven questionnaires had little or no content in the open-
ended questions.BMC Family Practice 2006, 7:61 http://www.biomedcentral.com/1471-2296/7/61
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The predominant pattern of belief was that HT 'use is
risky'. Samples of statements in this category were,
"They're not as safe as I thought." "They are not good for
you. They increase chances for cancer." "Hormones seem
to add to possible cancer problems." "They do not protect
the heart, more studies are needed, increased risk in
usage." Expressions of fear/concern about personal use of
HT were present in ten questionnaires. Sample statements
are, "Worried about long term health effects." "I am afraid
to take ERT."
The next most common pattern was 'vindication of prior
beliefs'. Sample statements were "Though I took them for
awhile I was never totally comfortable with the idea."
"Recent studies have confirmed my feelings that HRT is
not without its own set of risks." "If menopause is a nor-
mal process, why do I need to take drugs for it?" "I am a
firm believer in going as natural as possible and every-
thing I have read indicated I am on the right track."
In the category of 'benefit outweighs risk' examples are "I
believe the risk is less than the benefits." "After reading
and discussing the reports on their adverse effects, I don't
think I'm at risk for any of the adverse health effects". " I
know I am taking a risk by taking them (breast cancer). [I
take them] so that I feel like myself and not the wicked
witch."
A few women did not give evidence that they knew of any
recent change in recommendations or new research find-
ings. Examples are, "Hormone therapy is necessary for
women for its effects emotional and physical." " [I]
Believe they are helpful in maintaining hormone levels
during perimenopause." "They make me feel good and I
have no ill effects."
Some women were misinformed, believing that HT pro-
vides no health benefits even for bone strength, while the
WHI findings did confirm decreased risk for fractures and
colon cancer with HT.
Although we did not ask if women felt confused, six spon-
taneously expressed confusion or uncertainty such as "I
am confused" "I don't know what to do." " I don't know
what to believe."
A few women seemed to express anger. Sample statements
were, "I wish I had never taken HRT!" "...and we were lied
to by the manufacturers?!"
Subgroup analysis based on hormone use
Analysis was performed based on category of experience
with HT use into never-users, former users (quit before
July 2002), quitters (quit after July 2002 and not currently
using), restarters (quit after July 2002 but restarted and
currently using), and continuers (did not quit after July
2002 and currently using). Six questionnaires had missing
or contradictory responses precluding determination of
whether they were former users or quitters. Characteristics
of these subgroups are displayed in Table 2.
There were 43 (34%) respondents who were not using HT
in July 2002. Never-users (n = 18) were largely repre-
sented by the vindicated belief pattern. Some described
personal medical reasons for not using. Former users (n =
25) sometimes gave reasons for stopping based on side
effects of HT. Also in this group were women who used HT
for a while based on physician recommendation, though
never comfortable with the idea. Others stopped because
they had no perceived need to continue.
Recent quitters (n = 38) were a highly symptomatic and
concerned group. "My hot flashes have returned with
nearly the same intensity they were when I first started
using hormones. I am consulting with my doctor now to
find out what my options are." "I miss the effects of estro-
gen – positive attitude, more energy, higher metabolism
and sex drive." "I am not taking hormones now solely
Table 1: Demographic Characteristics of Study Sample (n = 127)
Characteristic Number Percentage
Year of birth
1933–1937 16 12.6
1938–1942 22 17.3
1943–1947 49 38.6
1948–1952 40 31.5
Race/ethnicity*
White not Hispanic 115 90.6
African American 3 2.4
Hispanic 3 2.4
Asian 1 0.8
Native American 3 2.4
Pacific Islander 2 1.6
Other 3 2.4
Prefer not to say 2 1.6
Education level
Less than high school 0 0.0
High school graduate 18 14.2
Some college 20 15.7
Bachelor's degree 22 17.3
Postgraduate education 67 52.8
Self-rated health status
Excellent 39 30.7
Good 64 50.4
Fair 16 12.6
Poor 7 5.5
Missing data 1 0.8
Current hot flashes
Yes 99 78.0
No 26 20.5
Missing data 2 1.6
* Instructions were to check all that applyBMC Family Practice 2006, 7:61 http://www.biomedcentral.com/1471-2296/7/61
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because I fear the side effects, I felt much better when I was
taking them." Some women were considering restart.
Restarters (n = 12) were also symptomatic and typically
felt unable to quit, at least not yet. The ages of these
women were relatively even across the span. Of these
respondents five had changed hormone therapy to a lower
dose or different formulation. Sample quotes are "Have
reduced the number of days on/off to see if I can stop alto-
gether. (not yet)" "Am tapering off, however hot flashes
and mood swings make it difficult."
Continuers (n = 28) were a relatively young and healthy
subgroup, yet the majority had used HT for more than 5
years. Most (59%) also answered yes to the question, 'Has
your opinion about hormone therapy changed?' and 39%
had changed dose or formulation. Predominantly,
women expressed a need for symptom relief as rationale
for their choice. "I take hormones because I feel better – I
can sleep and work without hot flashes." "I attempted
gradual reduction and had significant increase in hot
flashes." Nevertheless, fears about long-term use were
present in this group of women. "I am now concerned
about the long-range effect after 17 years of taking them."
"Worried about long-term health effects. Wasn't aware of
any when I started therapy 15 years ago."
Discussion
These findings show that women have largely accepted
the idea based on recent research findings that HT use is
risky. It might be expected that controversy about HT deci-
sions is abating as women stop using HT and/or never
start. However, the importance of symptom relief to peri-
and postmenopausal women should not be underesti-
mated.
Surveys of nationally representative samples of menopau-
sal women conducted in the 1990's found that 54% had
taken hormone therapy (HT) at some time in the peri-
menopausal years, with 32% for at least 5 years[6], and
that 38% of women aged 50–70 were currently taking
HT[7]. Rates as high as 50% and 85% of women taking
HT for at least 5 years and 2 years respectively, were
reported in one affluent, predominantly white, suburban
community[8]. The hormone use of women receiving care
in this practice prior to report of WHI results seems to
approximate the latter, community-based sample.
Prior qualitative studies on menopause and HT have pro-
vided useful information about women's views. Women
may believe that sometimes menopause requires medical
attention, but is primarily a marker or symbol of general
life-stage[9]. Although aging can be troubling to women,
even initially pessimistic women often reappraise the
menopause transition as a time of personal growth[10].
One New Zealand study[11] found that women utilize a
full range of socially available interpretations of HT as a
medicine, beauty product, drug (of dependence), and poi-
son. The decision to begin HT is affected by several
spheres of influence including internal, interpersonal rela-
tionships, external (i.e. cultural, such as ageism and sex-
ism), and perceived consequences of the treatment
decision[12]. A study[13] of HT decision-making has also
demonstrated that presentations about risk are inter-
preted within an individual's belief system. This study
adds insight into the dimension of reversal in medical rec-
ommendations.
Some quitters seemed to express grief. Others who are still
using appear to feel guilty about it, as if it were a vice. We
were impressed by the degree of emotion we perceived in
the written responses of these women. It was evident in
their choice of words as well as emphases given through
the use of large font, underlining, and exclamation points.
Our findings are consistent with the survey by Grady et al,
showing that the major predictor of resuming HT was
troublesome withdrawal symptoms[5]. The expressions
of emotion including worry and anger in this qualitative
data among women who quit, or tried to quit, taking HT
after July 2002 were not captured in prior studies. It is not
clear to women that the recommendation not to use HT
Table 2: Characteristics of Respondents by Category of HT Use Experience
Category of HT use Portion of sample 
entire sample*
More than 5 
years use
More than 10 years 
use
Estrogen 
only use
Good or excellent 
self-rated health
Moderate or severe 
hot flashes now
Moderate or severe hot 
flashes at worst ever
N % N % N% N % N%N% N %
N e v e r  u s e r s 1 8 1 4 0 0 0 0 0 0 1 5 8 363 31 3 7 2
Former users+ 25 20 10 40 2 8 9 43 15 64 5 20 17 68
Quitters# 38 30 26 68 10 26 8 21 32 84 15 39 27 71
Restarters& 1 2 9 9 7 5 65 0 4 3 3 75 865 01 1 9 2
Continuers^ 28 22 21 75 12 43 7 25 26 93 1 4 20 73
* Total less than 100% due to 6 responses with missing data to determine whether they were former users or recent quitters.
+ Stopped hormone therapy prior to July 2002.
# Stopped hormone therapy after July 2002, and not using at the time of response.
&Stopped hormone therapy after July 2002, and resumed use, using at time of response.
^ Respondents using HT at the time of response and that did not stop hormone therapy after July 2002.BMC Family Practice 2006, 7:61 http://www.biomedcentral.com/1471-2296/7/61
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for disease prevention and health promotion is different
from a recommendation not to use at all, even in the face
of troublesome symptoms.
Few studies have been undertaken to assess women's
quality of life with menopausal symptoms. Those few
have found an impact similar to that found in other stud-
ies of advanced heart failure[14,15]. While no overall ben-
efit for quality of life was found in the WHI[16],
participants were a relatively asymptomatic population.
On the other hand, women seen in primary care practice
on HT seem to be a highly symptomatic group of women.
A decision analysis by Kim et al in 2003 concluded that
with even a tiny improvement in quality of life with EPT,
the benefits of therapy for five years would outweigh the
risks for most women[17]. The difficulty of decision-mak-
ing for individual women is more complicated. Support
for difficult medical decisions should include individual-
ized risk communication[18]. Minelli et al performed a
decision analysis concluding that modeling should be tai-
lored to individual women to be useful in clinical prac-
tice[19]. Optimal decision-making about use of HT has
long been known to be influenced by women's prefer-
ences for health states, and is thus 'preference-sensi-
tive'[20]. Women's preferences about the trade-off
between long term risk and present symptom relief is the
most relevant aspect now and its assessment is complex.
Tools for decision support in the revised context of scien-
tific evidence are lacking.
It might be expected that women in our sample choosing
to use HT after results from the WHI report about EPT
would be mainly women taking estrogen only. However,
among both restarters and continuers the women taking
estrogen only were a minority. The results of the estrogen-
only therapy vs. placebo portion of the WHI was reported
in April 2004 and showed a non- significant excess of 2
events per 10,000 women years[21]. The present study
was conducted prior to availability of those results, so
their potential impact on patients' attitudes could not be
assessed. Those results did not receive the kind of public-
ity as the 2001 report, and women are therefore less likely
to know about them.
Study limitations
The study sample was not entirely representative of this
practice, since women who used HT were over sampled. In
addition, the majority of the sample was white and highly
educated. It is likely that these same women are more dis-
tressed by change in HT recommendations. While a sam-
ple size of 127 is small for a quantitative survey it is large
for a qualitative study.
Identifying women based on the prescription of an estro-
gen containing medication may inflate the numerator for
the practice-based rate of HT use, since not all women pre-
scribed HT are likely to be taking it. Nevertheless, con-
cerns of participants in this study may well represent those
of the large number of women who have either quit HT or
continue to use it. Future studies should systematically
recruit more women from race/ethnic groups other than
white non-Hispanics to clearly capture their perspectives.
Written answers to open-ended questions for qualitative
data collection is not as rich as interview or focus group
techniques. Results obtained suggest the need for further
qualitative research using those methods, as well as quan-
titative surveys of primary care and general population
women.
Conclusion
This sample of care-seeking women remains concerned
about pros and cons of HT. Strategies for decision support
regarding HT should explicitly take into account women's
preferences about symptom relief and trade-offs among
relevant risks. The discussion about such trade-offs is
complex and would benefit from the availability of new
decision support tools. They need accurate information
about how research results apply to them. Our findings
suggesting strong emotional overtones to decision-mak-
ing about HT leads us to believe that many women are
also likely to need emotional support in their transition
off or restart of hormones in order to limit their experi-
ence of suffering and/or guilt.
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